Direkt zum Inhalt
  1. Publizieren |
  2. Suche |
  3. Browsen |
  4. Neuzugänge rss |
  5. Open Access |
  6. Rechtsfragen |
  7. EnglishCookie löschen - von nun an wird die Spracheinstellung Ihres Browsers verwendet.

Ab interno gel implant in patients with primary open angle glaucoma and pseudoexfoliation glaucoma

Hengerer, Fritz H. ; Auffarth, Gerd U. ; Yildirim, Timur M. ; Conrad-Hengerer, Ina

In: BMC Ophthalmology, 18 (2018), Nr. 339. S. 1-8. ISSN 1471-2415

[thumbnail of 12886_2018_Article_989.pdf]
Vorschau
PDF, Englisch
Download (1MB) | Lizenz: Creative Commons LizenzvertragAb interno gel implant in patients with primary open angle glaucoma and pseudoexfoliation glaucoma von Hengerer, Fritz H. ; Auffarth, Gerd U. ; Yildirim, Timur M. ; Conrad-Hengerer, Ina steht unter einer Creative Commons Namensnennung 4.0

Zitieren von Dokumenten: Bitte verwenden Sie für Zitate nicht die URL in der Adresszeile Ihres Webbrowsers, sondern entweder die angegebene DOI, URN oder die persistente URL, deren langfristige Verfügbarkeit wir garantieren. [mehr ...]

Abstract

Purpose: To compare efficacy and safety results of an ab interno gel implant in patients with pseudoexfoliation glaucoma (PXG) and primary open angle glaucoma (POAG).

Methods: Retrospective analysis of the medical records of 110 consecutive eyes with open angle glaucoma who had received a XEN45 gel implant between March 2014 and June 2015. Intraocular pressure course, number of glaucoma medications, the need for additional intervention (including needling) and complications were evaluated until 12 months postoperatively.

Results: Data of 67 eyes with POAG and 43 eyes with PXG were analyzed. At 12 months postoperatively, the mean IOP had significantly decreased by 54.0% from preoperatively 31.85 ± 8.5 mmHg to 13.99 ± 2.6 mmHg in the POAG group, (p = 0.000; Wilcoxon test), and by 55.2% from 31.63 ± 9.0 mmHg to 13.28 ± 3.1 mmHg in the PXG group (p = 0.000; Wilcoxon test). The mean number of anti-glaucoma medications had significantly decreased from 3.25 ± 0.8 at baseline to 0.3 ± 0.7 medications at 12 months postoperatively in POAG eyes (p = 0.000; Wilcoxon test), and from 3.05 ± 1.0 to 0.3 ± 0.6 medications in PXG eyes (p = 0.000; Wilcoxon test). Hypotony (IOP ≤ 6 mmHg) was observed in 2 POAG eyes (3.0%) and in 5 PXG eyes (11.7%) at 1 month but normalized in all eyes at 12 months postoperatively. Severe complications were not observed. No statistically significant differences were found between PXG eyes and POAG eyes.

Conclusion: Our data indicate that the XEN45 gel implant provides significant and comparable reduction in IOP and anti-glaucoma medication during the one-year follow-up period in POAG as well as PXG eyes. This suggests that it may be a noteworthy alternative to traditional filtering procedures in patients with POAG and PXG respectively.

Dokumententyp: Artikel
Titel der Zeitschrift: BMC Ophthalmology
Band: 18
Nummer: 339
Verlag: BioMed Central
Ort der Veröffentlichung: London
Erstellungsdatum: 10 Jan. 2019 10:22
Erscheinungsjahr: 2018
ISSN: 1471-2415
Seitenbereich: S. 1-8
Institute/Einrichtungen: Medizinische Fakultät Heidelberg und Uniklinikum > Universitäts-Augenklinik
DDC-Sachgruppe: 610 Medizin
Leitlinien | Häufige Fragen | Kontakt | Impressum |
OA-LogoDINI-Zertifikat 2013Logo der Open-Archives-Initiative